Production of recombinant humanized monoclonal anti‐human neutrophil antigen (HNA) antibodies with potential applicability as standard antibodies

Abstract

AbstractBackgroundAntibodies against human neutrophil antigen (HNA) are involved in the pathogenesis of neonatal alloimmune neutropenia, autoimmune neutropenia, and transfusion‐related acute lung injury. The present methods for anti‐HNA antibody identification strongly depend on the presence of standard antisera with known allo/isospecificities. Here, we aimed to produce recombinant humanized antibodies to HNA from available mouse monoclonal antibodies (MoAbs).Study Design and MethodsRNAs were extracted from available hybridoma cells producing mouse anti‐HNA antibodies recognizing HNA‐1a (TAG‐1), ‐1b (TAG‐2), ‐2 (TAG‐4), and FcγRIIIb, and the cDNA was synthesized. Recombinant fragments consisting of the variable regions of the H and L chains of the mouse MoAb ligated to the constant region of human IgG were incorporated into an expression vector and transfected into CHO cells. Antibody specificity of the selected humanized monoclonal antibodies was confirmed, and tested by the participants of the ISBT Granulocyte Immunobiology Working Party (GIWP) workshop 2020.ResultsGIFT results confirmed the specific reactivity of TAGH‐1 to ‐4, except for a cross‐reactivity of TAGH‐2 with HNA‐1a/a neutrophils, only in flow‐cytometry. MAIGA results showed clear specificity of all humanized antibodies, but the selection of the appropriate capture monoclonal antibody was essential for the test. The results of the ISBT GIWP showed high concordance among the labs.ConclusionsThese are the first humanized monoclonal antibodies to HNA‐1 and HNA‐2 antigens produced and they will be important standard reagents for laboratories testing for neutrophil antibodies. We plan to have these humanized MoAbs available through WHO.